Cinda Biopharmaceutical Group was founded in 2011 with the mission and goal of developing high-quality biopharmaceuticals that ordinary people can use. The company has grown into a leading biopharmaceutical company and has built a fully integrated biopharmaceutical platform that meets global quality standards, integrating R&D, clinical development, manufacturing and commercialization capabilities. The company is committed to developing, producing and selling innovative drugs for major diseases such as oncology, CVM, autoimmunity, and ophthalmology. The company has established a rich product pipeline covering a range of innovative drug forms (including monoclonal antibodies, multispecific antibodies, immunocytokines, ADC, cell therapy and small molecule drugs). “Beginning with trust, achieving action”, the company adheres to the highest standards of industry standards, and hopes to work with industry colleagues to promote the development of the biopharmaceutical industry to meet the broad demand for first-class pharmaceuticals.
No Data
No Data